Phase 2
Completed N=50
N-Acetyl Cysteine in Trichotillomania
Trichotillomania
Source: ClinicalTrials.gov NCT00354770 ↗
Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jan 2014
Primary outcomePrimary: Massachusetts General Hospital Hairpulling Scale — 17.6; 16.7; 10.4; 16.0 units on a scale
Summary
This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Massachusetts General Hospital Hairpulling Scale |
17.6; 16.7; 10.4; 16.0 | — |
Eligibility Criteria
Inclusion Criteria
- men and women age 18-65;
- current DSM-IV trichotillomania
Exclusion Criteria
- unstable medical illness;
- history of seizures;
- myocardial infarction within 6 months;
- current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
- any thoughts of suicide;
- lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;
- previous treatment with N-Acetyl Cysteine;
- treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;
- 9) diagnosis of asthma
Data sourced from ClinicalTrials.gov (NCT00354770). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.